Loading company…
Xellsmart develops stem cell therapies and platforms for central nervous system diseases.
Founded in 2021 and based in Suzhou, China, Xellsmart develops stem cell therapies and related research platforms. Its work includes cell reprogramming, gene editing, and induced differentiation, with programs focused on Parkinson's disease and other central nervous system conditions. In April 2026, it raised CNY 500 million in Series C and Series C+ funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in